Mnemo Therapeutics Appoints Christine Foster, Ph.D. and Co-Founder Sebastian Amigorene, Ph.D. to Key Leadership Roles
Retrieved on:
Wednesday, November 30, 2022
Growth, GlaxoSmithKline, SUV39H1, Science, Laboratory, Ionis Pharmaceuticals, Intellia Therapeutics, University, Pharmacology, Multimedia, Responsibility, Therapy, Biotechnology, Degenerative disease, Sebastian Amigorena, Neuroscience, Senior, Acceleron Pharma, Foster, Brandeis University, Regeneron Pharmaceuticals, Teva Pharmaceuticals, Cancer, Research, Memory, Cell biology, CNRS, Immunotherapy, University of Massachusetts Medical School, Mnemos EP, Management, Pharmaceutical industry, Novartis, Princeton University, Immunology, Pfizer
Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.
Key Points:
- Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.
- "Christine brings a stellar history building meaningful value for biopharmaceutical companies by guiding business development and establishing strategic collaborations," said Mnemo Chief Executive Officer Robert LaCaze.
- "I am thrilled to contribute to the science and innovation taking place at Mnemo Therapeutics," Foster said.
- To learn more, visit https://mnemo-tx.com and follow Mnemo Therapeutics on Twitter (@MnemoTx) and LinkedIn.